Skip to Content
Merck
  • Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke.

Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke.

Nature communications (2020-05-20)
Lijing Kang, Huilin Yu, Xing Yang, Yuanbo Zhu, Xiaofei Bai, Ranran Wang, Yongliang Cao, Haochen Xu, Haiyu Luo, Lu Lu, Mei-Juan Shi, Yujing Tian, Wenying Fan, Bing-Qiao Zhao
ABSTRACT

Neovascularization and vascular remodeling are functionally important for brain repair after stroke. We show that neutrophils accumulate in the peri-infarct cortex during all stages of ischemic stroke. Neutrophils producing intravascular and intraparenchymal neutrophil extracellular traps (NETs) peak at 3-5 days. Neutrophil depletion reduces blood-brain barrier (BBB) breakdown and enhances neovascularization at 14 days. Peptidylarginine deiminase 4 (PAD4), an enzyme essential for NET formation, is upregulated in peri-ischemic brains. Overexpression of PAD4 induces an increase in NET formation that is accompanied by reduced neovascularization and increased BBB damage. Disruption of NETs by DNase 1 and inhibition of NET formation by genetic ablation or pharmacologic inhibition of PAD increases neovascularization and vascular repair and improves functional recovery. Furthermore, PAD inhibition reduces stroke-induced STING-mediated production of IFN-β, and STING knockdown and IFN receptor-neutralizing antibody treatment reduces BBB breakdown and increases vascular plasticity. Collectively, our results indicate that NET release impairs vascular remodeling during stroke recovery.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
PAD Inhibitor, Cl-amidine, Cl-amidine is a cell-permeable pan PAD inhibitor (IC₅₀ = 0.8, 6.2, and 5.9 µM for PAD1, PAD3, and PAD4, respectively). Inactivates the calcium bound form of PAD4 in an irreversible manner.
Sigma-Aldrich
Anti-NeuN Antibody, clone A60, clone A60, Chemicon®, from mouse